{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-003178","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.872410+00:00","generated_at":"2026-06-02T05:43:46.151279+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Phio Pharmaceuticals Q1 2024 net loss narrows to $2.2M; cash at $6.5M","bullets":["Cash of $6.5M at March 31, 2024, down from $8.5M at Dec 31, 2023.","Net loss of $2.2M for Q1 2024 vs $3.6M in prior-year quarter; R&D expenses fell 46% to $1.1M.","Phase 1b trial of PH-762 in skin cancers has enrolled 3 patients at 4 U.S. sites.","USPTO granted patents for INTASYL compounds RXI-185 and RXI-231 targeting age-related skin disorders."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-003178","json":"https://secwatch.observer/filing/0001683168-24-003178.json","markdown":"https://secwatch.observer/filing/0001683168-24-003178.md","text":"https://secwatch.observer/filing/0001683168-24-003178.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316824003178/0001683168-24-003178-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316824003178/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:43:46.151279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2811295b098af0ed8bf4bcbaa53b224ef490cf39","claim":"Phio Pharmaceuticals Corp. reported the three months ended March 31, 2024 results: net income Net loss was $2.2 million for the three months ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, Phio Pharmaceuticals Corp. (the “Company”) reported its financial results for the period ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316824003178/0001683168-24-003178-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Net income","value":"Net loss was $2.2 million for the three months ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}